Accéder au contenu
Merck

Discovery of triazines as selective PDE4B versus PDE4D inhibitors.

Bioorganic & medicinal chemistry letters (2014-07-08)
Timothy J Hagen, Xuesheng Mo, Alex B Burgin, David Fox, Zheng Zhang, Mark E Gurney
RÉSUMÉ

In this study we report a series of triazine derivatives that are potent inhibitors of PDE4B. We also provide a series of structure activity relationships that demonstrate the triazine core can be used to generate subtype selective inhibitors of PDE4B versus PDE4D. A high resolution co-crystal structure shows that the inhibitors interact with a C-terminal regulatory helix (CR3) locking the enzyme in an inactive 'closed' conformation. The results show that the compounds interact with both catalytic domain and CR3 residues. This provides the first structure-based approach to engineer PDE4B-selective inhibitors.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
A-33, ≥98% (HPLC)